Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The Cyclin D1 (CCND1) messenger RNA 3' untranslated region (UTR) is a critical regulatory segment of the CCND1 transcript that controls the stability and translation of the Cyclin D1 protein (Source: NCBI Gene ID: 595). This region contains numerous binding sites for microRNAs (miRNAs), such as the miR-15/16 family, and RNA-binding proteins that normally act to repress Cyclin D1 expression (Source: Bentwich et al., Nature Genetics, 2005). In various malignancies, particularly mantle cell lymphoma and breast cancer, the 3' UTR often undergoes shortening through alternative polyadenylation or genomic deletions (Source: Wiestner et al., Blood, 2007). This loss of regulatory sequences allows the mRNA to escape miRNA-mediated degradation, leading to the constitutive overexpression of Cyclin D1 and subsequent uncontrolled cell cycle progression from G1 to S phase (Source: Mayr and Bartel, Cell, 2009). As a therapeutic target, the CCND1 mRNA 3' UTR is being explored for intervention using antisense oligonucleotides (ASOs) and small interfering RNAs (siRNAs) designed to either degrade the transcript or block specific regulatory interactions (Source: Deshpande et al., Nature Reviews Drug Discovery, 2023). Targeting the mRNA directly offers a strategy to reduce protein levels at the source, potentially overcoming resistance mechanisms associated with downstream CDK4/6 inhibitors.
Sequence-specific binding to the 3' UTR to induce mRNA degradation via RNase H recruitment or to block interactions with stabilizing/destabilizing factors, thereby normalizing Cyclin D1 protein levels.
2 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Cyclin D1 messenger RNA 3' untranslated region (CCND1 mRNA 3' UTR).